GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » AegirBio AB (GREY:AEGBF) » Definitions » Debt-to-EBITDA

AegirBio AB (AegirBio AB) Debt-to-EBITDA : -2.87 (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is AegirBio AB Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

AegirBio AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.19 Mil. AegirBio AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $3.36 Mil. AegirBio AB's annualized EBITDA for the quarter that ended in Mar. 2024 was $-1.24 Mil. AegirBio AB's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 was -2.87.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for AegirBio AB's Debt-to-EBITDA or its related term are showing as below:

AEGBF' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.1   Med: -0.02   Max: -0.02
Current: -0.1

During the past 4 years, the highest Debt-to-EBITDA Ratio of AegirBio AB was -0.02. The lowest was -0.10. And the median was -0.02.

AEGBF's Debt-to-EBITDA is ranked worse than
100% of 439 companies
in the Medical Devices & Instruments industry
Industry Median: 1.26 vs AEGBF: -0.10

AegirBio AB Debt-to-EBITDA Historical Data

The historical data trend for AegirBio AB's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AegirBio AB Debt-to-EBITDA Chart

AegirBio AB Annual Data
Trend Dec19 Dec20 Dec21 Dec22
Debt-to-EBITDA
N/A -0.07 -0.02 -0.02

AegirBio AB Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Mar24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.01 -0.04 -0.58 -0.82 -2.87

Competitive Comparison of AegirBio AB's Debt-to-EBITDA

For the Medical Devices subindustry, AegirBio AB's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AegirBio AB's Debt-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, AegirBio AB's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where AegirBio AB's Debt-to-EBITDA falls into.



AegirBio AB Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

AegirBio AB's Debt-to-EBITDA for the fiscal year that ended in Dec. 2022 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.648 + 0.041) / -33.897
=-0.02

AegirBio AB's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.194 + 3.364) / -1.24
=-2.87

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2024) EBITDA data.


AegirBio AB  (GREY:AEGBF) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


AegirBio AB Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of AegirBio AB's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


AegirBio AB (AegirBio AB) Business Description

Traded in Other Exchanges
Address
Scheelevagen 27, Lund, SWE, SE-223 63
AegirBio AB is a Swedish diagnostic company that offers tests to monitor and optimize the dosage of biological drugs via its patented technology platform. The company's products include Monator - drug monitoring of tysabri in MS, Veritope, and Magniareader.

AegirBio AB (AegirBio AB) Headlines

No Headlines